The number of COVID-19 vaccination doses administered in the Netherlands rose to 36104942 as of Oct 27 2023. This dataset includes a chart with historical data for Netherlands Coronavirus Vaccination Total.

In the Netherlands, support for vaccines has declined significantly in the last four years. In 2018, over 92 percent of the Dutch public agreed vaccines were important for children to have, by 2022 this had dropped to only 72 percent.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

BackgroundIn 2011, a unique Q fever vaccination campaign targeted people at risk for chronic Q fever in the southeast of the Netherlands. General practitioners referred patients with defined cardiovascular risk-conditions (age >15 years). Prevalence rates of those risk-conditions were lacking, standing in the way of adequate planning and coverage estimation. We aimed to obtain prevalence rates retrospectively in order to estimate coverage of the Q fever vaccination campaign.MethodsWith broad search terms for these predefined risk-conditions, we extracted patient-records from a large longitudinal general-practice research-database in the Netherlands (IPCI-database). After validation of these records, obtained prevalence rates (stratified for age and sex) extrapolated to the Q fever high-incidence area population, gave an approximation of the size of the targeted patient-group. Coverage calculation addressed people actually screened by a pre-vaccination Q fever skin test and serology (coverage) and patients referred by their general practitioners (adjusted-coverage) in the 2011 campaign.ResultsOur prevalence estimate of any risk-condition was 3.1% (lower-upper limits 2.9-3.3%). For heart valve defects, aorta aneurysm/prosthesis, congenital anomalies and endocarditis, prevalence was 2.4%, 0.6%, 0.4% and 0.1%, respectively. Estimated number of eligible people in the Q fever high-incidence area was 11,724 (10,965-12,532). With 1330 people screened for vaccination, coverage of the vaccination campaign was 11%. For referred people, the adjusted coverage was 18%. Coverage was lowest among the very-old and highest for people aged 50–70 years.ConclusionThe estimated coverage of the vaccination campaign was limited. This should be interpreted in the light of the complexity of this target-group with much co-morbidity, and of the vaccine that required invasive pre-vaccination screening. Calculation of prevalence rates of risk-conditions based on the IPCI-database was feasible. This procedure proved an efficient tool for future use, when prevalence estimates for policy, implementation or surveillance of subgroup-vaccination or other health-care interventions are needed.

Netherlands NL: Immunization: Measles: % of Children Aged 12-23 Months data was reported at 94.000 % in 2016. This records a decrease from the previous number of 95.000 % for 2015. Netherlands NL: Immunization: Measles: % of Children Aged 12-23 Months data is updated yearly, averaging 95.000 % from Dec 1980 (Median) to 2016, with 37 observations. The data reached an all-time high of 96.000 % in 2014 and a record low of 91.000 % in 1981. Netherlands NL: Immunization: Measles: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Netherlands – Table NL.World Bank: Health Statistics. Child immunization, measles, measures the percentage of children ages 12-23 months who received the measles vaccination before 12 months or at any time before the survey. A child is considered adequately immunized against measles after receiving one dose of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

The Netherlands: Percent of children ages 12-23 months with measles immunization: The latest value from 2022 is 89 percent, a decline from 93 percent in 2021. In comparison, the world average is 84 percent, based on data from 187 countries. Historically, the average for the Netherlands from 1980 to 2022 is 94 percent. The minimum value, 89 percent, was reached in 2022 while the maximum of 96 percent was recorded in 1996.

This file contains data on COVID-19 vaccinations as registered in the national vaccination register "COVID vaccination Information and Monitoring System". (CIMS) of the National Institute for Public Health and the Environment (RIVM). Individuals have been asked for permission to share their vaccination data with CIMS for each COVID-19 vaccination. Percentage of people giving consent increases with successive vaccination rounds; in the basic series this was approximately 93%, in the booster 95% and in the repeat shot in the autumn round it was even more than 99%. NB: this is only known for the injections made by the Municipal Health Service (GGD); It is not known to other performers. Unauthorised vaccinations are not registered in CIMS. For a timeline of who was invited/eligible for COVID-19 vaccination from when, see table 9.3.2 in RIVM report 2022-0042 (https://doi.org/10.21945/RIVM-2022-0042)

More information on how to access the data:

https://www.cbs.nl/en-en/our-services/custom-and-microdata/microdata-self-research

Methodology

The National Institute for Public Health and the Environment (RIVM) receives from the various the vaccination programme details of the vaccinations carried out which have been authorised in order to: to be included in the national vaccination register CIMS. GGDGHOR Netherlands selects which Vaccination is passed on to CIMS. Vaccinations with the status ‘cancelled’ or ‘failed’ not passed on to CIMS. Furthermore, vaccinations are not delivered to CIMS if the batch number is missing. If multiple vaccinations are registered for the same client on the same day, a selection has been made to determine which vaccination will be transferred to CIMS. If vaccinations have the same round number, the completeness of the variables is first looked at vaccine name and batch number. If these variables are complete for all registrations, a selection made on the basis of the time of delivery. The vaccination that is the first by the GGD Submitted to CIMS. When there is another vaccination If you have been vaccinated less than a week before the selected vaccination, you will be selected vaccination from the CIMS data filtered and not (anymore) supplied to CIMS.

For performers other than the GGD, all vaccinations are delivered unchanged to CIMS. In CIMS the variable ' rank number' added. If two or more vaccinations have the same vaccination date Only the vaccination that was first provided will be given a ranking number. Most of the performers Give yourself a booster code (BS0x). For a small part of the executors who cannot do this themselves, the booster code in CIMS is assigned based on the date of campaign in progress on the The moment the vaccine was given.

Population

The population of this stock consists of all COVID-19 vaccinations registered in CIMS.

Netherlands NL: Immunization: DPT: % of Children Aged 12-23 Months data was reported at 94.000 % in 2017. This records a decrease from the previous number of 95.000 % for 2016. Netherlands NL: Immunization: DPT: % of Children Aged 12-23 Months data is updated yearly, averaging 97.000 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 98.000 % in 2004 and a record low of 94.000 % in 2017. Netherlands NL: Immunization: DPT: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Netherlands – Table NL.World Bank.WDI: Health Statistics. Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

This table provides information on DPTP vaccinations of infants. This concerns the number and percentage (vaccination rate) of infants in the Netherlands that have been vaccinated against it. For each reporting year, the vaccination rate was determined at the age of 1 and 2 years for infants born 3 years earlier. For example, for the 2015 reporting year, the vaccination rate was determined at the age of 1 and 2 years for infants born in 2012. To show how young people in the Netherlands are doing, the National Youth Monitor describes more than 70 subjects in addition to this subject. The subjects are called indicators. Data available from: 2006 Status of the figures: The figures in this table are final. Changes as of 21 July 2023: Figures for 2023 have been added. When will new numbers come out? The figures for 2024 will be added in July 2024.

Netherlands NL: Immunization: HepB3: % of One-Year-Old Children data was reported at 93.000 % in 2016. This records a decrease from the previous number of 94.000 % for 2015. Netherlands NL: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 71.500 % from Dec 2011 (Median) to 2016, with 6 observations. The data reached an all-time high of 94.000 % in 2015 and a record low of 20.000 % in 2012. Netherlands NL: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Netherlands – Table NL.World Bank: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

This table provides figures on DKTP vaccinations of infants. This concerns the number and percentage (vaccination rate) of infants on the islands of Bonaire, Saba and Sint Eustatius that have been vaccinated. For each reporting year, the vaccination rate was determined at the age of 2 years for infants born 3 years earlier. For example, for the 2018 reporting year, the vaccination rate was determined at the age of 2 for infants born in 2015. Since 10 October 2010, the islands of Bonaire, Saba and Sint Eustatius have been part of the Netherlands as special municipalities. In order to show how young people in the Netherlands are doing, the National Youth Monitor describes more than 70 topics in addition to this topic. The subjects are called indicators. Data available from 2013. Status of the figures: The figures up to and including 2022 are final. Changes as of 21 July 2023: Figures for 2023 have been added. The 2021 figures for Bonaire are not (yet) available due to the special circumstances surrounding the corona crisis. Those figures may become available later. When will new numbers come out? The figures for 2024 will be added in July 2024.

In the Netherlands, more than half of surveyed persons celebrating Sinterklaas in 2021 said they would only be celebrating the evening with friends and family members who are vaccinated, whether this was a deliberate choice or just because all invitees happened to be vaccinated. Only about three percent of Dutch respondents said they would spend the evening with unvaccinated people exclusively.

Immunization, measles (% of children ages 12-23 months) in Netherlands was reported at 89 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Netherlands - Immunization, measles (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.

A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed. We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands over 100 years using a validated deterministic dynamic transmission metapopulation model. Compared to 2vHPV, the 9vHPV strategy averted an additional 3,245 cases of and 825 deaths from 9vHPV-strain-attributable cancers, 4,247 cases of and 190 deaths from recurrent respiratory papillomatosis (RRP), and 1,009,637 cases of anogenital warts (AGWs), with an incremental cost-effectiveness ratio (ICER) of €4,975 per quality-adjusted life year (QALY) gained. The ICER increased in a scenario with increased HPV vaccination coverage rates and was relatively robust to one-way deterministic sensitivity analyses, with variation in the disease utility parameter having the most impact. When catch-up vaccination for individuals ≤26 years of age was added to the model, vaccinating with 9vHPV averted additional cancers and AGWs compared to 2vHPV vaccination. Our analyses predict that transitioning from a 2vHPV- to a 9vHPV-based vaccination strategy would be cost-effective in the Netherlands.

This file contains results of the Trend research dealing with rules of conduct. A representative group of people is asked every three weeks whether they comply with the rules of conduct set up in response to the Corona crisis and what they think of the rules of conduct.

The file contains national and per Security region data on: — Compliance with the rules of conduct — Support for the rules of conduct — Self-effectiveness (how difficult or easy do you find it to follow the rules of conduct?) — Response effectiveness (helps if everyone follows the rules of conduct?) — Social norm (do you see most people in your immediate environment following the rules of conduct?) — Affective response (are you worried about the coronavirus?) — Vaccination Preparedness — Corona-related complaints

Rules of conduct Compliance, acceptance, self-effectiveness, response effectiveness and social norm are sought for the following rules of conduct: — At_complaints_stay_at home — At_complaints_late_testing — Wear_mouth cap_in_OV — Wear_mouthcap_in_public_indoor spaces — Cough_niest_in_elbow — Hold_1_5m_distance — Receive_max_visitors_home — Avoid_pressure_places — Was_often_je_handen — Works at home

Data The file contains the following data: — Percentage or average — 95 % lower limit — 95 % upper limit — Change from the previous measurement — Number of respondents in the sample By Security Region, per measurement period by indicator category per indicator

Records The file contains the following set of records per questionnaire round: — A record for each Security Region in the Netherlands by indicator @-@ category per indicator — A record for total percentages in the Netherlands by indicator @-@ category per indicator per gender designation, by age category per educational level

Indicator categories The following indicator categories are distinguished: Compliance: Are the requested rules of conduct observed (current behaviour)? Supporting surface: To what extent do you support the rule of conduct? Help_rules: Supposing everyone would follow the government’s rules of conduct, how well would that help to prevent the spread of the coronavirus? Difficulty: How difficult or easy do you find it to comply with the rule of conduct? Next door_environment: Do most people in the immediate vicinity of the surveyed follow the rules of conduct? Are you worried about the coronavirus? Vaccination readiness: Would you like to be vaccinated if there’s a vaccine later? Complaints: Percentage of people with corona-related symptoms

Variables Description of variables: Date_of_report: Date and time when the data file was created by the RIVM.

Date_of_measurement: Date on which the measurement started. The measuring time is a week. The measurement therefore took place on that date and six days later.

Wave Tracking number of the measurement

Region_code: Netherlands and Security Region Code. The Netherlands has code NL00. See also: https://www.cbs.nl/nl-nl/cijfers/detail/84721NED?q=Veiligheid

Region_name: The Netherlands and the name of the Security Region. This is the name of the Security Regions as used so far in various RIVM reports and reports, and may differ slightly from the naming as indicated in the code list of CBS (see link above for variable Security_region_code). See also: https://www.rijksoverheid.nl/onderwerpen/veiligheidsregios-en-crisisbeheersing/veiligheidsregios

Subgroup_category: Dimensions in which the figures are broken down: — All (Total; No breakdown) — Sex (Male/Women) — Age (16-24 years/25-39 years/40-54 years/55-69 years/70+) — Educational level (Low/Middle/High)

Subgroup: Title of dimension (see Subgroup_category)

Indicator_category: Categorisation of the indicators: — Compliance — Support surface — Help_rules — Difficulty — Neighboring_environment — Care — Vaccination Preparedness — Complaints

Indicator: Compliance, Support, Help_rules, Moeite and Near_environment for the following rules of conduct: — At_complaints_stay_at home — At_complaints_late_testing — Wear_mouth cap_in_OV — Wear_mouthcap_in_public_indoor spaces — Cough_niest_in_elbow — Hold_1_5m_distance — Receive_max_visitors_home — Avoid_pressure_places — Was_often_je_handen — Works at home Concerns: — Care_over_Coronacrisis Vaccination readiness: — Yes — Yes_first_know_al_corona_gehad — No_al_corona_gehad — No_other_reason — No_care_over_safety_vaccine — Do not know Complaints at the time of completing the questionnaire: — At least_one_corona_related

Sample_sise: Number of respondents who replied to a question

Figure_type: Figure species (Percentage/Average) Value Calculated Value of the Indicator Lower_limit 95 % confidence interval lower limit Upper_limit 95 % confidence interval upper limit Change_wrt_previous_measurement Significant difference from the previous measurement period (-1 = decrease/0 = unchanged/1 = increased)

Immunization, Hib3 (% of children ages 12-23 months) in Netherlands was reported at 90 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. Netherlands - Immunization, Hib3 (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on June of 2025.

IntroductionIn the 2022 multicountry mpox (formerly named monkeypox) outbreak, several countries offered primary preventive vaccination (PPV) to people at higher risk for infection. We study vaccine acceptance and its determinants, to target and tailor public health (communication-) strategies in the context of limited vaccine supply in the Netherlands.MethodsOnline survey in a convenience sample of gay, bisexual and other men who have sex with men, including transgender persons (22/07-05/09/2022, the Netherlands). We assessed determinants for being (un)willing to accept vaccination. We used multivariable multinominal regression and logistic regression analyses, calculating adjusted odds ratios (aOR) and 95 percent confidence-intervals. An open question asked for campaigning and procedural recommendations.ResultsOf respondents, 81.5% (n = 1,512/1,856) were willing to accept vaccination; this was 85.2% (799/938) in vaccination-eligible people and 77.7% (713/918) in those non-eligible. Determinants for non-acceptance included: urbanization (rural: aOR:2.2;1.2–3.7; low-urban: aOR:2.4;1.4–3.9; vs. high-urban), not knowing mpox-vaccinated persons (aOR:2.4;1.6–3.4), and lack of connection to gay/queer-community (aOR:2.0;1.5–2.7). Beliefs associated with acceptance were: perception of higher risk/severity of mpox, higher protection motivation, positive outcome expectations post vaccination, and perceived positive social norms regarding vaccination. Respondents recommended better accessible communication, delivered regularly and stigma-free, with facts on mpox, vaccination and procedures, and other preventive options. Also, they recommended, “vaccine provision also at non-clinic settings, discrete/anonymous options, self-registration” to be vaccinated and other inclusive vaccine-offers (e.g., also accessible to people not in existing patient-registries).ConclusionIn the public health response to the mpox outbreak, key is a broad and equitable access to information, and to low-threshold vaccination options for those at highest risk. Communication should be uniform and transparent and tailored to beliefs, and include other preventive options. Mpox vaccine willingness was high. Public health efforts may be strengthened in less urbanized areas and reach out to those who lack relevant (community) social network influences.

Health effect of influenza vaccination based on electronic medical records collected within a general practitioner (GP)-based influenza surveillance system in the Netherlands. Contrary to expectations, influenza vaccinees have GP consultation rates for clinically diagnosed influenza, ARI and pneumonia that are 24-33% higher compared to unvaccinated individuals. The lower back pain finding suggests that the increase in consultation rates is partially caused by confounding. Importantly, considering the data are not laboratory-confirmed, our results cannot be linked directly to influenza, but only to respiratory illnesses in general. Date Submitted: 2021-04-21

In nineteenth century Belgium, smallpox vaccination was available but was never made compulsory. For this reason, the number of deaths due to smallpox fluctuated regularly (although data before 1864 is scarce*), and the Great Pandemic of the 1870s caused the number of smallpox deaths in Belgium to skyrocket to 4.2 thousand per million people in 1871. Several sources suggest that smallpox had a similar impact in the Netherlands throughout the early and mid-1800s, however the Netherlands introduced mandatory vaccination for all children who were to be enrolled in school in 1873, and following the Great Pandemic the Netherlands' death rate was much lower than that of Belgium. The last natural case of smallpox was recorded in the Netherlands in 1900 (making it the fourth country in the world to eradicate the disease on a national level), while the last endemic case of smallpox in Belgium occurred in 1926. Data for Italy and Hungary is also scarce throughout the century, however Hungary introduced mandatory vaccination and revaccination in 1887, while Italy did the same in 1888; over the next decade we can see that the average number of smallpox deaths in these countries decreased greatly, and endemic cases of smallpox were eliminated in Hungary in 1923, and in 1947 in Italy.

Only patients included from the high-incidence area, stratified according to age groups and sex.Risk-conditions for chronic Q fever of screened patients in the vaccination campaign in 2011.